CN
Core Areas

Keymed Biosciences consistently explore the disease areas that need to be solved urgently, focus on the autoimmune and tumor therapies,  establish a highly competitive pipeline, and rapidly promote the R&D of multiple innovative drugs.


  • 30+

    Projects under R&D

  • 9

    Entered Clinical Stage

  • 3

    Bispecific Antibody

  • 1

    ADC

Science & Technology

Meet the GMP Standards of NMPA, FDA and EMA

Efficiently Synthesize the Internal Development and Production Capability, Establish a Comprehensive and Integrated Biological R&D Platform

Innovation Runs through the Whole Industrial Chain of R&D, Production and Future Commercial Operation